NCT07014449招募中1 期
An Open-Label, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WBC100 Capsules in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Hangzhou Weben Pharma Co., Ltd1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2024年11月3日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Incidence and severity of dose-limiting toxicities (DLTs)
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are:
- What is the safety and tolerability profile of WBC100 in R/R AML patients?
- Can WBC100 effectively induce remission in R/R AML patients?
Participants will:
- Take WBC100 capsules orally once daily in 28-day treatment cycles;
- Undergo regular safety assessments, including adverse event monitoring and laboratory tests;
- Provide blood samples for pharmacokinetic (PK) analysis;
- Have their remission status and efficacy evaluated according to the ELN2022 criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent and compliance with study procedures;
- •Male or female participants aged ≥18 years at the time of consent;
- •Diagnosis of relapsed or refractory acute myeloid leukemia (R/R AML) according to the 2016 World Health Organization (WHO) classification;
- •ECOG PS 0-2;
- •Life expectancy ≥3 months;
- •Adequate bone marrow reserve and organ function as defined below:
- •Bone marrow reserve: Peripheral WBC < 25 × 10⁹/L (leukocyte-reducing agents are allowed, with a washout period of at least 5 half-lives prior to study drug administration);
- •Coagulation: International normalized ratio (INR) ≤ 2;
- •Hepatic function: Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN. In cases of hepatic involvement: ALT or AST ≤ 5 × ULN, and TBIL ≤ 3 × ULN;
- •Renal function: Creatinine clearance ≥60 mL/min (Cockcroft-Gault), or serum creatinine ≤1.5 × ULN;
- •Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%; QTcF ≤450 ms for males, ≤470 ms for females.
- •Female participants of childbearing potential and fertile male participants with partners of childbearing potential must use medically approved contraception during treatment and for 6 months after the final dose.
排除标准
- •Known hypersensitivity to WBC100 capsules or any of their excipients;
- •Diagnosis of acute promyelocytic leukemia (APL);
- •Diagnosis of mixed phenotype acute leukemia, chronic myeloid leukemia in blast crisis, or AML transformed from myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN);
- •Subjects with relapse after allogeneic HSCT, grade ≥ 2 acute GVHD, extensive chronic GVHD requiring immunosuppressive therapy, or autologous HSCT within the past 90 days;
- •Subjects who have undergone major surgery, have active ulcers, or have unhealed wounds within 28 days prior to the first dose;
- •Received other investigational drugs or treatments within 28 days prior to the first administration, or are still within the safety follow-up period of another clinical trial;
- •Subjects with a history of severe cardiovascular or cerebrovascular conditions, including but not limited to:
- •Significant arrhythmias or conduction disorders (e.g., ventricular arrhythmias, Grade II-III AV block);
- •Thromboembolic events requiring anticoagulation or presence of vena cava filter;
- •NYHA Class III-IV heart failure;
- •Poorly controlled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment).
- •Evidence of severe or uncontrolled systemic diseases, such as refractory effusions, poorly controlled diabetes, or significant disorders of the psychiatric, neurological, cardiovascular, respiratory, endocrine, gastrointestinal, hepatic, or renal systems;
- •History or presence of immunodeficiency, autoimmune disease requiring systemic immunosuppressants, or organ transplantation;
- •Congestive heart failure, aortic dissection, stroke (excluding lacunar infarct), unstable angina, myocardial infarction, bypass surgery, or pulmonary embolism within 180 days prior to first dosing;
- •Known risk factors for QT prolongation, including congenital long QT syndrome or drug-induced arrhythmia history;
- •Positive for syphilis antibodies, HIV, active HBV infection (HBsAg+ or HBcAb+ with HBV DNA ≥1000 IU/mL), or active HCV infection (HCV Ab+ with detectable HCV RNA);
- •Active infection requiring systemic treatment, including uncontrolled bacterial, viral, or fungal infections;
- •Gastrointestinal conditions preventing oral drug intake or absorption, such as severe vomiting, chronic diarrhea, intestinal stoma, malabsorption, or inability to swallow;
- •Use of strong CYP450 inhibitors/inducers that cannot be stopped ≥7 days before dosing;
- •Receipt of monoclonal antibodies, ADCs, radiotherapy within 28 days (14 days for localized radiotherapy), cytotoxic chemotherapy, targeted small molecules within 14 days or 5 half-lives, or CAR-T therapy within 100 days;
- •Receipt of any live or attenuated vaccines (e.g., influenza, varicella) within 28 days;
- •History of other malignancies within 2 years, except adequately treated basal cell carcinoma, carcinoma in situ of cervix or breast, or squamous cell carcinoma of the skin;
- •History of psychiatric or neurological disorders that may interfere with protocol compliance;
- •Inability to tolerate venous blood draws;
- •Pregnant or breastfeeding women, or women with positive serum hCG during screening;
- •Any condition deemed by the investigator to make the subject unsuitable for study participation.
研究组 & 干预措施
WBC100 Capsules
Experimental
Participants will take WBC100 capsules orally once daily in 28-day cycles. This arm includes a dose-escalation phase using an accelerated titration combined with the traditional '3+3' design. After a single-patient observation at 0.5 mg, three patients will be enrolled per cohort at each subsequent dose level (1.0, 1.5, 2.0, 2.5, and 3.0 mg). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal.
干预措施: WBC100 QD (Drug)
结局指标
主要结局
Incidence and severity of dose-limiting toxicities (DLTs)
时间窗: During the first treatment cycle (28 days)
Evaluated according to NCI-CTCAE version 5.0.
Incidence and severity of treatment-emergent adverse events (TEAEs)
时间窗: From first dose to 28 days after the last dose
Includes lab abnormalities, physical exam findings, vital signs, and ECG changes.
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
时间窗: 28 days
Based on observed DLTs.
次要结局
- Cmax(28 days)
- Tmax(28 days)
- AUC0-t(28 days)
- AUC0-inf(28 days)
- T1/2(28 days)
- λz(28 days)
- CL/F(28 days)
- Vz/F(28 days)
- Cmax, ss(28 days)
- Cmin, ss(28 days)
- Cavg(28 days)
- Tmax, ss(28 days)
- ARAUC(28 days)
- CLss/F(28 days)
- Vss/F(28 days)
- ARCmax(28 days)
- DF(28 days)
- Duration of response (DOR)(2 years)
- Event-free survival period (EFS)(2 years)
- Overall survival (OS)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Breast NeoplasmsNCT05463952Pfizer6
已完成
1 期
A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy VolunteersPK in Healthy VolunteersNCT06698861PharmaEssentia30
招募中
1 期
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT06158477Chengdu JOYO pharma Co., Ltd.75
已完成
1 期
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsSARS-CoV-2 InfectionNCT05142306Emergent BioSolutions23
已完成
1 期
A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney DiseaseRenal ImpairmentNCT03913000Idorsia Pharmaceuticals Ltd.32